HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. - Wikidata - wikimedia - TriplyDB

HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.

HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.

http://www.wikidata.org/entity/Q36957145

about

Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer Regulation of ERBB3/HER3 signaling in cancer Orchestration of ErbB3 signaling through heterointeractions and homointeractions.Pseudokinases: update on their functions and evaluation as new drug targets.Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.Pharmacological targeting of the pseudokinase Her3 A RTK-based functional RNAi screen reveals determinants of PTX-3 expression.Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3.Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.Two dimensions in targeting HER2.HER2 signaling regulates HER2 localization and membrane retention.Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.Digital histologic analysis reveals morphometric patterns of age-related involution in breast epithelium and stroma.Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor.The promise of anti-ErbB3 monoclonals as new cancer therapeutics Molecular pathways: HER3 targeted therapy Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.HER3 as a Therapeutic Target in Cancer.Overcoming resistance to HER2 inhibitors through state-specific kinase binding.

P2860

Q26773907-98465DDE-798B-4390-983C-F424B727A2B9 Q27024334-066F38D1-4175-416C-A48F-F2A6FD907693 Q27306737-CDDFF638-08E5-4120-9251-9B5E7AE7E78A Q30397636-391E0D1C-E841-4394-B975-9B083C25782B Q30419961-A525BDC8-2C80-4948-8049-55A57872ABCA Q33601653-3140B773-7FBA-4242-A287-1163FF5F6BB3 Q33772914-38217001-8F09-4FDE-A675-4CB5B956C00D Q34036131-37AF3957-E5FF-489F-95F5-71E32149CE13 Q34514043-96A4ADD6-FA58-40B0-8CCF-02B984DD0EB0 Q34662196-5873B987-230D-4704-9CA1-BE8C6CBA346D Q34752052-CDB34C75-2844-4F3B-A8C0-C44E138366DB Q35140121-E0A5BD18-3913-4F87-B012-7E7442C0AAE2 Q35174240-9309EEA3-6601-4947-B684-9A8A78F725CA Q35551911-28A8D455-DEE4-44EA-93E6-CF7989A6D87B Q35682599-31F129D0-9C55-45A2-B053-7B0650AC05E4 Q35890128-DB18A40B-7374-4485-BE01-E91B2E91FC94 Q35895143-CDF6266F-E4C3-43BD-B6C2-3A538554B8D1 Q36331808-3FB60995-0B0A-4D33-BB7A-B32A4EA90D45 Q36348663-526DBE28-CD77-4DF0-9DAA-DCD7239DBDEC Q36356248-D11ACBBA-DDC1-478B-83A0-A587A6050E91 Q36359705-BE5D6882-6E64-4B7A-AC1E-DA549C4EB76A Q36505107-779C91E6-32D2-404B-9F5A-1CA4FA2D426B Q36562299-9EA708C7-486F-4034-B4AC-B51937599927 Q36585794-022B64AE-9437-4DA4-929E-184BA0095478 Q36619622-E55D77A1-64D0-4831-9708-FF576A5A0FC3 Q36729450-CEB4C9A3-2627-4B07-BB12-34B716742E28 Q36879470-0BD96C0B-19E7-4598-8B10-8226550F7E97 Q36986301-9A2E6F42-ACA2-4A5B-A6AB-CB44FEEECE7E Q37124053-4A90C6A9-566F-45F4-AF08-F28B5A366E2B Q37200831-09F734F6-9B31-4DB1-AD1D-FB830F8B25CD Q37215964-4AEC2F63-8FBB-4C46-B1B0-EA7716882350 Q37247862-EE3CDCC3-2808-4E19-A7A6-0F7197D1BAA2 Q37407344-6743E7B6-9C37-412D-B9BF-DF4CC06345A7 Q37715501-4A54BA20-39DE-4492-B108-81D0B3E9B3D7 Q38034347-49EC3DD8-7D78-48D7-A15C-A5789FC4891C Q38187398-A268AB7F-7A05-40CF-97AA-88790011664F Q38214802-3B467B5F-A76A-4239-B2BC-041016396054 Q38364887-8ED8D43F-050B-4B9D-A7AF-7C1B2617DD43 Q38725101-4F9E50DC-9EC2-4BD6-A814-3684EA65742B Q38740481-3FD52BB1-0A65-4C90-B204-E1216E13F998

P2860

HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.

http://www.wikidata.org/entity/Q36957145

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

HER3 is required for HER2-indu ...... pithelium and tumor formation.

@en

type

label

HER3 is required for HER2-indu ...... pithelium and tumor formation.

@en

prefLabel

HER3 is required for HER2-indu ...... pithelium and tumor formation.

@en

P1433

Q36957145-889F1406-46A0-412C-8FAF-A5F8C421680D

P1476

Q36957145-43E8031C-18D8-404C-B8C8-28777B214AFF

P2093

Q36957145-2AFCACCA-8CA2-4D3F-AADE-6D03F942ACF9

Q36957145-45FB8357-43FE-420E-B4E7-6A8558762E00

Q36957145-54661584-FB52-41D4-B401-06111F7F1623

Q36957145-55F54A86-0D85-4E3B-AA1D-88E70A2152D7

Q36957145-7A8C2105-6587-40E6-A4BA-46C73AD5620E

Q36957145-8A5C760A-C2D1-49FA-9EF2-E4078383F109

Q36957145-928F0FA6-FC57-4402-BE8D-12E6CC5941D3

Q36957145-AA6A6855-45F2-4765-8C5D-384878D2E3C7

Q36957145-B17C4C82-6F17-468B-8B14-59277AA628BE

Q36957145-B4BE19B2-669E-44A2-B95E-996BC7F1FFA9

P2860

Q36957145-08C2696D-588A-443A-9250-10F4EA2C0FE3

Q36957145-0A668E2D-BB50-48AB-98FC-FEC933D50919

Q36957145-0EC373AF-9A3F-44F2-B2D8-05FF1900FC62

Q36957145-16C37E58-F7B8-49AC-A58B-C6B1F432433C

Q36957145-275248D2-313F-4947-8A39-151C83BA174C

Q36957145-2D20A823-BA20-422D-A498-676EDD1DC580

Q36957145-340BE48B-B9A7-457E-BD43-452085F50877

Q36957145-35AF90EA-9CF1-47EC-A61F-B9FDA1A1D0DB

Q36957145-3D390519-EF3C-4A5A-8F3B-B6F7A45861AC

Q36957145-3FA940E9-41B5-458C-809B-84A5F122F93E

P304

Q36957145-BC99DBB3-255E-4D6B-9337-6C408850FBF7

P31

Q36957145-4F2EB739-C1C9-40A4-8CDA-A1E34FC623CB

P356

Q36957145-B0CE8171-F0F8-43C0-B4B5-A68835EDEAA1

P407

Q36957145-B4E0EAD2-B28D-4803-8F85-74FBD29A80D9

P433

Q36957145-87ACC645-F379-4B8B-B57E-2A3BA37D9C02

P478

Q36957145-4988A31A-AC1A-4738-A9AC-4AB8B9DD9DBB

P50

Q36957145-469AAD75-E3F6-4568-B670-6CFBE3F24631

P577

Q36957145-F07385A8-DC9C-4FD7-9E2F-4F73C412BA02

P698

Q36957145-566BBB7A-23AE-41D6-8F71-491B9E36E030

P932

Q36957145-73D7765D-0951-4E12-9479-9D8C9FDA23F8

P356

0008-5472.CAN-11-3594

P1433

Cancer Research

P1476

HER3 is required for HER2-indu ...... epithelium and tumor formation

@en

P2093

Cammie Rinehart

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Christian Young

http://www.w3.org/2001/XMLSchema#string

David B Vaught

http://www.w3.org/2001/XMLSchema#string

Donna J Hicks

http://www.w3.org/2001/XMLSchema#string

Frank Wheeler

http://www.w3.org/2001/XMLSchema#string

Jamie C Stanford

http://www.w3.org/2001/XMLSchema#string

Rebecca S Cook

http://www.w3.org/2001/XMLSchema#string

Violeta Sánchez

http://www.w3.org/2001/XMLSchema#string

William J Muller

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the PI3K signaling pathway in cancer

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Generalized lacZ expression with the ROSA26 Cre reporter strain

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas

Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase

ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

P304

2672-2682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-3594

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22461506

http://www.w3.org/2001/XMLSchema#string

P932

3693553

http://www.w3.org/2001/XMLSchema#string